Printer Friendly

MorphoSys issued patent for HuCAL antibody library.

MorphoSys AG (Munich, Germany; 49-89-899-27-439) announced that the United States Patent and Trademark Office has granted the company a new patent covering its Human Combinatorial Antibody Library (HuCAL). The United States Patent, 6,300,064), entitled "Protein/(poly)peptide libraries" covers methods for the construction of synthetic, fully modular human antibody libraries based on in silico consensus sequences. The application on which the patent is based was submitted to the United States Patent and Trademark Office in 1998. A related HuCAL patent was issued in Australia in the year 2000, and further patent applications are currently pending in Canada, Europe and Japan.

"The HuCAL patent family sits at the core of our technologies and the grant of this patent significantly strengthens our patent portfolio. Moreover, the speed in which the United States patent office granted our patent application points to the clear and undisputed novelty and inventiveness of the HuCAL technology," commented Dr. Thomas von Rueden, Chief Scientific Officer of MorphoSys AG.

Recently another patent was granted to MorphoSys in the United States (US 6,294,353), entitled "Targeted hetero-association of recombinant proteins to multi-functional complexes", further strengthening MorphoSys' intellectual property portfolio. The patent covers multifunctional protein complexes formed by certain hetero-associating domains.

To-date, MorphoSys has four patents granted and more than 40 applications pending worldwide. The patents and pending applications cover a variety of different technologies, including antibody libraries, screening methods such as the EST and CysDisplay technologies, certain antibody fragment formats, and specific antibodies.

MorphoSys develops and applies innovative technologies for the production of synthetic antibodies, which accelerate drug discovery and target characterization. Founded in 1992, the company's proprietary Human Combinatorial Antibody Library (HuCAL) technology is used by researchers worldwide for human antibody generation. The company currently has licensing and research collaborations with Bayer AG (Berkeley, California/USA), Biogen Inc. (Cambridge, Massachusetts/USA), Centocor Inc. (Malvern, Pennsylvania/USA), DuPont Pharmaceuticals Inc. (Wilmington, Delaware/USA), Eos Biotechnology Inc. (San Francisco, California/USA), GPC Biotech AG (Munich/Germany), Hoffmann-La Roche AG (Basel/Switzerland), ImmunoGen Inc. (Cambridge, Massachusetts/USA), Millennium Inc. (Cambridge, Mass/USA), Oridis Biomed GmbH (Graz/Austria) and ProChon Biotech Ltd. (Rehovot/Israel).
COPYRIGHT 2001 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:MorphoSys issued patent for HuCAL antibody library.
Publication:BIOTECH Patent News
Article Type:Brief Article
Geographic Code:4EUGE
Date:Oct 1, 2001
Previous Article:NeoTherapeutics receives patent for serotonin-like hypoxanthines.
Next Article:Harvard Bioscience receives 'notice of allowability' for organism sorting technology.

Related Articles
American Biogenetic obtains patent for the treatment of malignant and benign tumors.
Crucell announces the issuance of major phage antibody patent.
Genentech antibody patent issues - licensed to MedImmune.
GPC Biotech announces issuance of United States patent for detecting diseased cells.
MorphoSys wins final ruling in patent dispute with CAT.
Epicyte announces broad patent covering production of antibodies in plants.
Sunol Molecular issued a patent for a novel antibody.
MorphoSys widens scope of United States patent for HuCAL technology.
MorphoSys and Novartis forge therapeutic antibody alliance.
MorphoSys and Novartis forge therapeutic antibody alliance.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters